Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 2
1987 3
1988 1
1995 1
1996 1
1997 1
1999 2
2000 2
2001 1
2002 1
2005 2
2006 2
2008 3
2010 4
2013 1
2014 1
2016 1
2017 1
2018 2
2021 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of an α1 -blocker plus mirabegron compared with an α1 -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta-analysis.
Herschorn S, Tarcan T, Jiang YH, Chung E, Abdul Hadi F, Steup A, Sumarsono B. Herschorn S, et al. Among authors: steup a. Neurourol Urodyn. 2024 Mar;43(3):604-619. doi: 10.1002/nau.25399. Epub 2024 Jan 30. Neurourol Urodyn. 2024. PMID: 38291827 Review.
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD; mirabegron PMR-PASS study group. Hoffman V, et al. Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7. Epub 2021 Jul 8. Drug Saf. 2021. PMID: 34236595 Free PMC article.
Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, Steup A, Lange B, Rauschkolb C, Haeussler J. Afilalo M, et al. Among authors: steup a. Clin Drug Investig. 2010;30(8):489-505. doi: 10.2165/11533440-000000000-00000. Clin Drug Investig. 2010. PMID: 20586515 Clinical Trial.
German universities.
Steup A. Steup A. Science. 1996 Nov 8;274(5289):905a. doi: 10.1126/science.274.5289.905a. Science. 1996. PMID: 17798608 No abstract available.
Toe agnosia in Gerstmann syndrome.
Tucha O, Steup A, Smely C, Lange KW. Tucha O, et al. Among authors: steup a. J Neurol Neurosurg Psychiatry. 1997 Sep;63(3):399-403. doi: 10.1136/jnnp.63.3.399. J Neurol Neurosurg Psychiatry. 1997. PMID: 9328265 Free PMC article.
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
Buynak R, Shapiro DY, Okamoto A, Van Hove I, Rauschkolb C, Steup A, Lange B, Lange C, Etropolski M. Buynak R, et al. Among authors: steup a. Expert Opin Pharmacother. 2010 Aug;11(11):1787-804. doi: 10.1517/14656566.2010.497720. Expert Opin Pharmacother. 2010. PMID: 20578811 Clinical Trial.
37 results